About Neurocrine
Neurocrine is a company based in San Diego (United States) founded in 1992 was acquired by Immedica in January 2026.. Neurocrine has raised $10 million across 4 funding rounds from investors including BB Biotech, Immedica and MQS Management. The company has 1,800 employees as of December 31, 2024. Neurocrine has completed 1 acquisition, including Neurocrine UK. Neurocrine offers products and services including Medicines and Clinical Studies. Neurocrine operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, PTC Therapeutics, Biohaven Pharmaceutical and Crinetics, among others.
- Headquarter San Diego, United States
- Employees 1800 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Neurocrine Biosciences, Inc.
-
Annual Revenue
$2.36 B24.81as on Dec 31, 2024
-
Net Profit
$341.3 M36.68as on Dec 31, 2024
-
EBITDA
$624.1 M49.99as on Dec 31, 2024
-
Total Equity Funding
$10 M (USD)
in 4 rounds
-
Latest Funding Round
-
Investors
BB Biotech
& 3 more
-
Employee Count
1800
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Immedica
(Jan 08, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Neurocrine
Neurocrine is a publicly listed company on the NASDAQ with ticker symbol NBIX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Neurocrine
Neurocrine offers a comprehensive portfolio of products and services, including Medicines and Clinical Studies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Treatments for neurological and neuropsychiatric disorders
Investigations into potential treatments for rare diseases
Unlock access to complete
Leadership Team
82 people
Software Development Team
37 people
Neuropsych Team
34 people
Senior Team
34 people
Neurology Team
33 people
Regional Team
32 people
Product Management Team
31 people
Operations Team
27 people
Unlock access to complete
Funding Insights of Neurocrine
Neurocrine has successfully raised a total of $10M across 4 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Last Round
-
First Round
First Round
(17 Dec 2009)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Post-IPO - Neurocrine | Valuation |
investors |
|
| Mar, 2019 | Amount | Post-IPO - Neurocrine | Valuation |
investors |
|
| Apr, 2017 | Amount | Post-IPO - Neurocrine | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Neurocrine
Neurocrine has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include BB Biotech, Immedica and MQS Management. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on tech sectors
|
Founded Year | Domain | Location | |
|
Offers fundamentally driven quantitative global macro investment strategies as a registered adviser.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Neurocrine
Neurocrine has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Neurocrine UK. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Hormone therapeutics for rare and chronic endocrine diseases are developed.
|
2004 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Neurocrine
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Neurocrine Comparisons
Competitors of Neurocrine
Neurocrine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, PTC Therapeutics, Biohaven Pharmaceutical and Crinetics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Small molecule drugs for rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapies for the treatment of endocrine-related diseases and cancers
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Neurocrine
Frequently Asked Questions about Neurocrine
When was Neurocrine founded?
Neurocrine was founded in 1992 and raised its 1st funding round 17 years after it was founded.
Where is Neurocrine located?
Neurocrine is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Neurocrine?
Kevin Gorman is the current CEO of Neurocrine.
Is Neurocrine a funded company?
Neurocrine is a funded company, having raised a total of $10M across 4 funding rounds to date. The company's 1st funding round was a Post-IPO of $518M, raised on Dec 17, 2009.
How many employees does Neurocrine have?
As of Dec 31, 2024, the latest employee count at Neurocrine is 1,800.
What is the annual revenue of Neurocrine?
Annual revenue of Neurocrine is $2.36B as on Dec 31, 2024.
What does Neurocrine do?
Developer of small molecule therapeutics for endocrine and CNS disorders. The companys product line include elagolix, a gonadotropin-releasing hormone antagonist for endometriosis and uterine leiomyoma, and NBI-98854 a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.
Who are the top competitors of Neurocrine?
Neurocrine's top competitors include Jazz Pharmaceuticals, Crinetics and PTC Therapeutics.
What products or services does Neurocrine offer?
Neurocrine offers Medicines and Clinical Studies.
Is Neurocrine publicly traded?
Yes, Neurocrine is publicly traded on NASDAQ under the ticker symbol NBIX.
How many acquisitions has Neurocrine made?
Neurocrine has made 1 acquisition, including Neurocrine UK.
Who are Neurocrine's investors?
Neurocrine has 4 investors. Key investors include BB Biotech, Immedica, MQS Management, and Venrock.
What is Neurocrine's ticker symbol?
The ticker symbol of Neurocrine is NBIX on NASDAQ.